Breast and Ovarian Cancer Genomics
1 – 10 of 99
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2026
-
Mark
Proliferation- and cytotoxic immune signatures identify chemotherapy-responsive bladder tumors in a molecular subtype dependent manner
- Contribution to journal › Article
-
Mark
Integrated prediction of lung cancer histology and molecular profiles from small bronchoscopic tumor specimens
- Contribution to journal › Article
-
Mark
Comprehensive comparison of homologous recombination deficiency predictors in early-stage triple-negative breast cancer
- Contribution to journal › Article
-
Mark
Dynamic assessment of proliferation to guide response-adapted therapy in the setting of neoadjuvant chemotherapy in ER+/HER2- breast cancer
- Contribution to journal › Article
-
Mark
Homologous recombination deficiency in primary ER-positive and HER2-negative breast cancer
- Contribution to journal › Article
-
Mark
Multiomics assessment of lung adenocarcinoma subtypes defined through tumor purity-adjusted DNA methylation
- Contribution to journal › Article
- 2025
-
Mark
Tertiary lymphoid structures in high-grade serous tubo-ovarian carcinoma : anatomical site matters
- Contribution to journal › Article
-
Mark
Navigating Immune Landscapes in Ovarian Cancer - Spatial and Genomic Insights into High-Grade Serous and Endometriosis-Associated Histotypes
(2025) In Lund University, Faculty of Medicine Doctoral Dissertation
- Thesis › Doctoral thesis (compilation)
-
Mark
Fusions4U: a resource of validated and annotated gene fusions in 328 cancer cell lines
- Contribution to journal › Article
-
Mark
Genomic characterization of the HER2-enriched intrinsic molecular subtype in primary ER-positive HER2-negative breast cancer
- Contribution to journal › Article
